Nanjing Leads Biolabs Co., Ltd. presented new clinical data on LBL-034 at the 67th Annual Meeting of the American Society of Hematology (ASH) in Orlando. The results, featuring a median progression-free survival (PFS) trending beyond one year, spotlight a potential breakthrough in hematology.